InAADR

Protein Information

Protein Name: Potassium voltage-gated channel subfamily H member 2 (Q12809)
Gene Name: KCNH2
Description:
PDB ID: 1BYW
Protein Family: PF00027, PS50042
Protein Category: Ion Channels

This panel provides drug-protein interaction and their ADRs along with references

Interacting Drugs Toxicity Mechanism Reference
Amiodarone Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Astemizole Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Atenolol Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Cisapride Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Cisapride Torsade De Pointes Increased risk of drug-induced torsade de pointes [ ADR Type 2 ] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
Clarithromycin Torsade De Pointes Increased risk of drug-induced torsade de pointes. [ ADR Type 2 ] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
Covera Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Diltiazem Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Domperidone Cardiac Arrhythmias Role of systems pharmacology in understanding drug adverse events
Droperidol Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Erythromycin Torsade De Pointes Increased risk of drug-induced torsade de pointes. [ ADR Type 2 ] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
Flecainide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Grepafloxacin Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Hydrochlorothiazide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Levacetylmethadol Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Mexiletine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Moricizine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Pacerone Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Procainamide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Pronestyl Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Propafenone Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Propranolol Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Quinidine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Quinidine Torsade De Pointes Increased risk of drug-induced torsade de pointes. [ ADR Type 2 ] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
Sertindole Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Sotalol Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Terfenadine Arrhythmias Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development
Terfenadine Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Terfenadine Torsade De Pointes Increased risk of drug-induced torsade de pointes [ ADR Type 2 ] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
Tikosyn Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Tocainide Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
Toprol XL Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II
verapamil Sudden Cardiac Death Sudden cardiac death due to long-QT syndrome [ ADR Type 2 ] Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II

InAADR: Drug-Protein-ADRs database